BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jung DE, Park SB, Kim K, Kim C, Song SY. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway. Sci Rep 2017;7:10921. [PMID: 28883618 DOI: 10.1038/s41598-017-11094-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Nepali K, Liou JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J Biomed Sci 2021;28:27. [PMID: 33840388 DOI: 10.1186/s12929-021-00721-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wen N, Lv Q, Du ZG. MicroRNAs involved in drug resistance of breast cancer by regulating autophagy. J Zhejiang Univ Sci B 2020;21:690-702. [PMID: 32893526 DOI: 10.1631/jzus.B2000076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fan C, Kam S, Ramadori P. Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer. Cancers (Basel) 2021;13:5250. [PMID: 34680398 DOI: 10.3390/cancers13205250] [Reference Citation Analysis]
4 Kim YD, Park SM, Ha HC, Lee AR, Won H, Cha H, Cho S, Cho JM. HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. J Cancer 2020;11:4059-72. [PMID: 32368288 DOI: 10.7150/jca.44622] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
5 Li Y, Zheng J, Huo Q, Chen Z, Chen J, Xu X, Papaccio G. Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation. Stem Cells International 2022;2022:1-15. [DOI: 10.1155/2022/3632549] [Reference Citation Analysis]
6 Ho TCS, Chan AHY, Ganesan A. Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight. J Med Chem 2020;63:12460-84. [PMID: 32608981 DOI: 10.1021/acs.jmedchem.0c00830] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 27.0] [Reference Citation Analysis]
7 Garcia-Sampedro A, Gaggia G, Ney A, Mahamed I, Acedo P. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. J Clin Med 2021;10:566. [PMID: 33546207 DOI: 10.3390/jcm10040566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zhou Q, Guo J, Huang W, Yu X, Xu C, Long X. Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2. Mol Oncol 2020;14:2231-50. [PMID: 32335998 DOI: 10.1002/1878-0261.12700] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
9 Pobbati AV, Hong W. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics 2020;10:3622-35. [PMID: 32206112 DOI: 10.7150/thno.40889] [Cited by in Crossref: 61] [Cited by in F6Publishing: 40] [Article Influence: 30.5] [Reference Citation Analysis]
10 Adeshakin AO, Adeshakin FO, Yan D, Wan X. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy. Front Immunol 2022;13:781660. [DOI: 10.3389/fimmu.2022.781660] [Reference Citation Analysis]
11 Yoon GE, Jung JK, Lee YH, Jang BC, In Kim J. Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production. Naunyn Schmiedebergs Arch Pharmacol 2020;393:491-500. [PMID: 31655853 DOI: 10.1007/s00210-019-01749-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
12 Zhou T, Zhong Y, Hu Y, Sun C, Wang Y, Wang G. PM2.5 downregulates miR-194-3p and accelerates apoptosis in cigarette-inflamed bronchial epithelium by targeting death-associated protein kinase 1. Int J Chron Obstruct Pulmon Dis 2018;13:2339-49. [PMID: 30122914 DOI: 10.2147/COPD.S168629] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
13 Gautvik KM, Günther CC, Prijatelj V, Medina-Gomez C, Shevroja E, Rad LH, Yazdani M, Lindalen E, Valland H, Gautvik VT, Olstad OK, Holden M, Rivadeneira F, Utheim TP, Reppe S. Distinct Subsets of Noncoding RNAs Are Strongly Associated With BMD and Fracture, Studied in Weight-Bearing and Non-Weight-Bearing Human Bone. J Bone Miner Res 2020;35:1065-76. [PMID: 32017184 DOI: 10.1002/jbmr.3974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Pan X, Wang G, Wang B. Ectopic expression of microRNA-874 represses epithelial mesenchymal transition through the NF-κB pathway via CCNE1 in cholangiocarcinoma. Cell Signal 2021;82:109927. [PMID: 33476715 DOI: 10.1016/j.cellsig.2021.109927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Robak P, Dróżdż I, Jarych D, Mikulski D, Węgłowska E, Siemieniuk-Ryś M, Misiewicz M, Stawiski K, Fendler W, Szemraj J, Smolewski P, Robak T. The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients. Cancers (Basel) 2020;12:E2569. [PMID: 32916955 DOI: 10.3390/cancers12092569] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
16 Lenders M, Brand E. Fabry disease – a multisystemic disease with gastrointestinal manifestations. Gut Microbes 2022;14:2027852. [DOI: 10.1080/19490976.2022.2027852] [Reference Citation Analysis]
17 Roca MS, Di Gennaro E, Budillon A. Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors. J Clin Med 2019;8:E912. [PMID: 31247937 DOI: 10.3390/jcm8070912] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
18 Hillyar C, Rallis KS, Varghese J. Advances in Epigenetic Cancer Therapeutics. Cureus 2020;12:e11725. [PMID: 33391954 DOI: 10.7759/cureus.11725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
19 Bae EH, Kim IJ, Song JH, Choi HS, Kim CS, Eom GH, Kim I, Cha H, Cho JM, Ma SK, Kim SW. Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats. Int J Mol Sci 2019;20:E508. [PMID: 30691015 DOI: 10.3390/ijms20030508] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
20 He X, Luo X, Dong J, Deng X, Liu F, Wei G. Long Non-Coding RNA XIST Promotes Wilms Tumor Progression Through the miR-194-5p/YAP Axis. Cancer Manag Res 2021;13:3171-80. [PMID: 33883934 DOI: 10.2147/CMAR.S297842] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Pant K, Peixoto E, Richard S, Gradilone SA. Role of Histone Deacetylases in Carcinogenesis: Potential Role in Cholangiocarcinoma. Cells 2020;9:E780. [PMID: 32210140 DOI: 10.3390/cells9030780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Wu D, Qiu Y, Jiao Y, Qiu Z, Liu D. Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy. Front Oncol 2020;10:560487. [PMID: 33262941 DOI: 10.3389/fonc.2020.560487] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Han H, Yang B, Nakaoka HJ, Yang J, Zhao Y, Le Nguyen K, Bishara AT, Mandalia TK, Wang W. Hippo signaling dysfunction induces cancer cell addiction to YAP. Oncogene 2018;37:6414-24. [PMID: 30068939 DOI: 10.1038/s41388-018-0419-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
24 Kubatka P, Kello M, Kajo K, Samec M, Jasek K, Vybohova D, Uramova S, Liskova A, Sadlonova V, Koklesova L, Murin R, Adamkov M, Smejkal K, Svajdlenka E, Solar P, Samuel SM, Kassayova M, Kwon TK, Zubor P, Pec M, Danko J, Büsselberg D, Mojzis J. Chemopreventive and Therapeutic Efficacy of Cinnamomum zeylanicum L. Bark in Experimental Breast Carcinoma: Mechanistic In Vivo and In Vitro Analyses. Molecules 2020;25:E1399. [PMID: 32204409 DOI: 10.3390/molecules25061399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
25 Zheng XH, Wang LL, Zheng MZ, Zhong JJ, Chen YY, Shen YL. RGFP966 inactivation of the YAP pathway attenuates cardiac dysfunction induced by prolonged hypothermic preservation. J Zhejiang Univ Sci B 2020;21:703-15. [PMID: 32893527 DOI: 10.1631/jzus.B2000026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kubatka P, Kello M, Kajo K, Samec M, Liskova A, Jasek K, Koklesova L, Kuruc T, Adamkov M, Smejkal K, Svajdlenka E, Solar P, Pec M, Büsselberg D, Sadlonova V, Mojzis J. Rhus coriaria L. (Sumac) Demonstrates Oncostatic Activity in the Therapeutic and Preventive Model of Breast Carcinoma. Int J Mol Sci 2020;22:E183. [PMID: 33375383 DOI: 10.3390/ijms22010183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
27 Kubatka P, Uramova S, Kello M, Kajo K, Samec M, Jasek K, Vybohova D, Liskova A, Mojzis J, Adamkov M, Zubor P, Smejkal K, Svajdlenka E, Solar P, Samuel SM, Zulli A, Kassayova M, Lasabova Z, Kwon TK, Pec M, Danko J, Büsselberg D. Anticancer Activities of Thymus vulgaris L. in Experimental Breast Carcinoma in Vivo and in Vitro. Int J Mol Sci 2019;20:E1749. [PMID: 30970626 DOI: 10.3390/ijms20071749] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
28 Flint E, Triantafyllou E, Bernsmeier C. TAM Receptors in the Pathophysiology of Liver Disease. Livers 2022;2:15-29. [DOI: 10.3390/livers2010002] [Reference Citation Analysis]
29 Autin P, Blanquart C, Fradin D. Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors. Cancers (Basel) 2019;11:E1530. [PMID: 31658720 DOI: 10.3390/cancers11101530] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
30 Tang C, Yuan P, Wang J, Zhang Y, Chang X, Jin D, Lei P, Lu Z, Chen B. MiR-192-5p regulates the proliferation and apoptosis of cholangiocarcinoma cells by activating MEK/ERK pathway. 3 Biotech 2021;11:99. [PMID: 33552829 DOI: 10.1007/s13205-021-02650-w] [Reference Citation Analysis]
31 Choi HS, Song JH, Kim IJ, Joo SY, Eom GH, Kim I, Cha H, Cho JM, Ma SK, Kim SW, Bae EH. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease. Sci Rep 2018;8:11546. [PMID: 30068917 DOI: 10.1038/s41598-018-30008-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
32 Cigliano A, Chen X, Calvisi DF. Current challenges to underpinning the genetic basis for cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:511-26. [PMID: 33888034 DOI: 10.1080/17474124.2021.1915128] [Reference Citation Analysis]
33 Lee NH, Kim SJ, Hyun J. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer. Biomedicines 2021;9:347. [PMID: 33808155 DOI: 10.3390/biomedicines9040347] [Reference Citation Analysis]